Chemerin Produced By Mesenchymal Stromal Cells (MSC) Is an Important Factor for In Vivo macrophage Migration

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 1195-1195
Author(s):  
Paola Vinci ◽  
Antonio Bastone ◽  
Silvia Schiarea ◽  
Erica Dander ◽  
Mario Salmona ◽  
...  

Abstract Mesenchymal Stromal Cells (MSC) are multipotent cells currently used for treating several inflammatory disorders thanks to their ability to modulate the immune response. However, the mechanisms by which MSC are able to suppress the immune response have not been fully understood. Chemerin has been recently identified as a chemotactic protein, secreted as a precursor, named Prochemerin, and converted into its active form through the proteolitic cleavage of the last six-seven amino acids at the C-terminal domain by different serine and cysteine proteases derived from the fibrinolitic, coagulation and inflammatory cascade. In particular, we observed that both human and mouse bone marrow-derived MSC were able to produce Chemerin under basal conditions and its production was strongly increased after stimulation with inflammatory cytokines. The aim of this study was to understand whether Chemerin produced by MSC is involved in their potent immune-modulatory activity. Chemerin was immune-purified from supernatant of human MSC (MSC-Chem) and utilized for measuring in vitro migration index (MI) of pre-B cells expressing the human ChemR23 receptor (L1.2-ChemR23). MSC-Chem was able to induce the migration of ChemR23-expressing cells in a dose-depend manner (MI 1nM=85, MI 5nM=480, MI 10nM=1131). However, recombinant human (rh)-chemerin induced higher migration of L1.2-ChemR23 cells compared to MSC-Chem (MI 5nM=1938), suggesting that only a fraction of MSC-Chem was converted into its active form by MSC themselves. In accordance, LC/MS mass spectrometry analysis on purified MSC-Chem did not identify the active form of the protein. Interestingly, pre-incubation of MSC-Chem with Neutrophil Elastase and Cathepsin L induced a strong migration of L1.2-ChemR23 cells compared to MSC-Chem alone (MI MSC-Chem alone 1 nM=23.33; MI MSC-Chem 1 nM + Neutrophil Elastase=328; MI MSC-Chem 1 nM + Cathepsin L=4950; p=0.002), suggesting that MSC-Chem were converted in its active form, after cleavage by proteases. Starting from these data, we established an in vivo migration assay by injecting under the abdominal skin of C57BL6 mice a mix of matrigel and murine (m)MSC (secreting or not Chemerin). After 5 days, the matrigel plug was excided, digested and infiltrating immune cells were analyzed by FACS analysis. Chemerin production by mMSC was totally abrogated by using RNA interference approach (sChem-MSC). Interestingly, mMSC features, such as phenotype and differentiation ability, were not affected by the gene-silencing process. Preliminary results showed that 5 days after injection, scramble Chem-MSC were able to recruit macrophages (CD45+CD11b+F4/80+ cells) into the matrigel plug. On the other hand, sChem-MSC drastically decreased their ability to induce macrophages migration, (sChem-MSC mean=2.38%, range=0.8%-6.4%; scramble MSC mean=8.2%; range=4%-11.5%; p=0.01; n=3). These findings identify a new mechanism by which MSC, through Chemerin production, attract macrophages in vivo. Further studies are needed to understand whether recruited macrophages are also affected by the immunomodulatory activity of MSC Disclosures No relevant conflicts of interest to declare.

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 1590-1590
Author(s):  
Paola Vinci ◽  
Antonio Bastone ◽  
Erica Dander ◽  
Annalisa Del Prete ◽  
Mario Salmona ◽  
...  

Abstract Although several studies have shown that Mesenchymal Stromal Cells (MSCs) are used for treating inflammatory diseases, the mechanisms underlying their capacity to inhibit the inflammatory response are not understood. Chemerin is an immunoregulatory protein with chemotactic activity, secreted by different cell subsets as a precursor and converted into its active form through the proteolitic cleavage of the last six-seven amino acids at the C-terminal domain. We showed that MSCs are able to produce Chemerin (MSC-Chem) and its production depends on the conditions used for MSC culture. In particular, we observed that MSC cultured with platelet lysate produced high amount of chemerin under basal conditions, and its secretion was strongly increased after stimulation with inflammatory cytokines. Therefore, in order to understand if MSC-Chem is involved in the immunoregulatory function of MSCs, we performed biochemical and functional analysis. To evaluate the chemotactic activity of MSC-Chem, we performed migration assays using a pre-B cell line expressing the human ChemR23 receptor (L1.2-ChemR23). L1.2-ChemR23 cells were able to migrate in response to rh-chemerin in a dose depend manner, until the concentration of 5nM (at 0.2 nM MI=2472, range=2201-2743; at 1 nM MI=9392, range=8902-9882; at 5nM MI=11737, range=11665-11809, at 10 nM MI=2904, range=3261-2548; p= 0.01). Interestingly, MSC-Chem induced the migration of L1.2-ChemR23 cells at 1 nM, 5 nM and 10nM (MI=85, 480, 1131, respectively). However, at equivalent concentrations, rh-chemerin was able to induce a stronger L1.2-ChemR23 migration compared to MSC-Chem, suggesting that within MSCs supernatant only a fraction of the protein was in the active form. In accordance, the biochemical analysis obtained by the LC/MS mass spectrometry identified chemerin active form (with the last peptide Chem144-Chem147) only in rh-chemerin, but not in MSC-Chem (Chem144-Chem147), confirming that most of the MSC-Chem was in the inactive form. Chemerin has been reported to be cleaved by several serine and cysteine proteases, which are then able to activate or inactivate chemerin, depending on the cleavage site. We analysed the expression of chemerin serine-cysteine proteases by MSCs both under basal conditions and after stimulation with inflammatory cytokines. RT-PCR showed that MSC express low levels of neutrophil elastase (mean 2-ΔΔCt=1, range=0.55-1.4 n=3) compared to PBMCs (positive control) (mean 2-ΔΔCt=234.5, range=201.3-284.7 n=3) and its expression did not significantly increase after 24h, 48h or 72h of stimulation with inflammatory cytokines (mean 2-ΔΔCt = 5, range=3.1-5.8; mean 2-ΔΔCt = 3.0, range=2.6 -3.7; mean 2-ΔΔCt = 2,1, range= 1.9-2.4; respectively, n=3). MSCs also expressed cathepsin K (mean 2-ΔΔCt = 7.4, range= 4.4-10.2, n=2), and its levels did not increase after stimulation with inflammatory cytokines (after 24h mean 2-ΔΔCt = 8.5, range= 3.75-19.1; after 48h mean 2-ΔΔCt = 8.8, range=5.0-12.6 and after 72h mean 2-ΔΔCt= 10.5, range=9.4-11,8; n=2). In conclusion, we demonstrated that MSCs were able to produce Chemerin and directly cleave it in its active form, although only partially. We speculate that, when infused in vivo during inflammation, MSCs produce chemerin as a precursor, which is then converted in its active form by cysteine and serine proteases, highly expressed at peripheral inflamed tissues. Further in vivo studies are needed to show whether activated Chemerin can then induce ChemR23-expressing cells migration towards MSC, to better exert their anti-inflammatory activity. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4898-4898
Author(s):  
Moïra François ◽  
Raphaëlle Romieu-Mourez ◽  
Sophie Stock-Martineau ◽  
Jacques Galipeau

Abstract Antigen cross-presentation is the mechanism by which exogenous antigens can be presented by major histocompatibility complex (MHC) class I molecules to CD8+ T cells. This process is efficiently performed by professional antigen presenting cells (APC) such as dendritic cells and macrophages. Recently, we and others have shown that IFN-g enables the upregulation of the expression of MHC class I & II molecules by marrow-derived Mesenchymal Stromal Cells (MSCs) and that MHC II-mediated antigen presentation can lead to cell-mediated protective immunity to xenoantigens [Stagg et al., Blood March 2006]. These findings led us to investigate whether MSCs also possess the ability to cross-present antigens via MHC class I. Using antigen presentation assays performed on murine MSC in the presence of MHC class I-restricted ovalbumin (OVA)-specific CD8+ T hybridoma cells or purified primary CD8+ T lymphocytes from OT1 transgenic mice, we demonstrated that MSC can robustly and effectively cross-present exogenous antigens via MHC class I molecules upon IFN-g pre-treatment in a manner comparable to professional APCs like macrophages. Use of transporter associated with antigen processing (TAP-1)-deficient mice and proteasome inhibitors suggested a MHC class I machinery-dependent pathway. Cross-presentation by IFN-g-activated MSC was also observed to be suppressed by TGF-b and regulated by cell density. In vivo, IFN-g-treated, OVA-pulsed MSCs administered to normal C57Bl/6 mice led to an effective OVA-specific, T cell cytotoxic immune response, leading to the rejection of OVA-expressing EG7 lymphoma cells. In conclusion, our findings suggest that cross-presentation properties of MSC could play a role in their effectiveness as conditional APCs in vivo and this property may be exploited as a therapeutic cell-based immune biopharmaceutical for treatment of cancer or infectious disease.


2021 ◽  
Vol 10 (13) ◽  
pp. 2925
Author(s):  
Manuel Sanchez-Diaz ◽  
Maria I. Quiñones-Vico ◽  
Raquel Sanabria de la Torre ◽  
Trinidad Montero-Vílchez ◽  
Alvaro Sierra-Sánchez ◽  
...  

Mesenchymal Stromal Cells (MSCs) are of great interest in cellular therapy. Different routes of administration of MSCs have been described both in pre-clinical and clinical reports. Knowledge about the fate of the administered cells is critical for developing MSC-based therapies. The aim of this review is to describe how MSCs are distributed after injection, using different administration routes in animal models and humans. A literature search was performed in order to consider how MSCs distribute after intravenous, intraarterial, intramuscular, intraarticular and intralesional injection into both animal models and humans. Studies addressing the biodistribution of MSCs in “in vivo” animal models and humans were included. After the search, 109 articles were included in the review. Intravenous administration of MSCs is widely used; it leads to an initial accumulation of cells in the lungs with later redistribution to the liver, spleen and kidneys. Intraarterial infusion bypasses the lungs, so MSCs distribute widely throughout the rest of the body. Intramuscular, intraarticular and intradermal administration lack systemic biodistribution. Injection into various specific organs is also described. Biodistribution of MSCs in animal models and humans appears to be similar and depends on the route of administration. More studies with standardized protocols of MSC administration could be useful in order to make results homogeneous and more comparable.


2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Maurice A. Canham ◽  
John D. M. Campbell ◽  
Joanne C. Mountford

Abstract More than seven months into the coronavirus disease -19 (COVID-19) pandemic, infection from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 21.2 million cases and resulted in over 760,000 deaths worldwide so far. As a result, COVID-19 has changed all our lives as we battle to curtail the spread of the infection in the absence of specific therapies against coronaviruses and in anticipation of a proven safe and efficacious vaccine. Common with previous outbreaks of coronavirus infections, SARS and Middle East respiratory syndrome, COVID-19 can lead to acute respiratory distress syndrome (ARDS) that arises due to an imbalanced immune response. While several repurposed antiviral and host-response drugs are under examination as potential treatments, other novel therapeutics are also being explored to alleviate the effects on critically ill patients. The use of mesenchymal stromal cells (MSCs) for COVID-19 has become an attractive avenue down which almost 70 different clinical trial teams have ventured. Successfully trialled for the treatment of other conditions such as multiple sclerosis, osteoarthritis and graft versus host disease, MSCs possess both regenerative and immunomodulatory properties, the latter of which can be harnessed to reduce the severity and longevity of ARDS in patients under intensive care due to SARS-CoV-2 infection.


Cells ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 403
Author(s):  
Girolamo Di Maio ◽  
Nicola Alessio ◽  
Ibrahim Halil Demirsoy ◽  
Gianfranco Peluso ◽  
Silverio Perrotta ◽  
...  

Brown-like adipocytes can be induced in white fat depots by a different environmental or drug stimuli, known as “browning” or “beiging”. These brite adipocytes express thermogenin UCP1 protein and show different metabolic advantages, such as the ability to acquire a thermogenic phenotype corresponding to standard brown adipocytes that counteracts obesity. In this research, we evaluated the effects of several browning agents during white adipocyte differentiation of bone marrow-derived mesenchymal stromal cells (MSCs). Our in vitro findings identified two compounds that may warrant further in vivo investigation as possible anti-obesity drugs. We found that rosiglitazone and sildenafil are the most promising drug candidates for a browning treatment of obesity. These drugs are already available on the market for treating diabetes and erectile dysfunction, respectively. Thus, their off-label use may be contemplated, but it must be emphasized that some severe side effects are associated with use of these drugs.


Sign in / Sign up

Export Citation Format

Share Document